Journal Home
Search for

Volume 75, Issue 1, Pages 14-26 (January 2007)


View previous. 4 of 22 View next.

Regulation of hormone-sensitive lipase in islets

Wen-Jun ShenabCorresponding Author Informationemail address, Yu Lianga, Jenny Wanga, Kenji Haradaa, Shailja Patela, Sara A. Michiec, Jun-Ichi Osugad, Shun Ishibashie, Fredric B. Kraemerab

Received 22 November 2005; accepted 3 May 2006. published online 09 June 2006.

Abstract 

An unique isoform of hormone-sensitive lipase (HSL) is expressed in β-cells. Recent findings suggest that HSL could be involved in the regulation of glucose stimulated insulin secretion (GSIS), however, these findings are controversial. To test the hypothesis that HSL is involved in control of normal GSIS via changes in its expression and/or activity in response to stimuli, we examined the effects of free fatty acid (FFA) loading and glucagon like peptide-1 (GLP-1) stimulation on the regulation of HSL expression and activity. With prolonged FFA loading, there was increased expression of β-cell HSL and increased HSL hydrolytic activity in clonal β-cells. Short-term treatment with GLP-1 increased HSL activity without changing the expression of the β-cell isoform of HSL. Basal insulin secretion was increased, whereas GLP-1 potentiation of GSIS was decreased in islets isolated from HSL−/− mice, as compared to islets from wild type mice. Furthermore, using PancChip 2.2 cDNA microarrays (NIDDK consortium), the gene expression profile in the islets of HSL−/− mice was compared with wild type mice. Results showed changes in several metabolic pathways due to changes in lipid homeostasis caused by inactivation of HSL. Quantitative PCR for selected genes also revealed changes in genes that are related to insulin secretion, such as UCP-2. Therefore, these results suggest that the β-cell isoform of HSL is involved in maintaining lipid homeostasis in islets and contributes to the proper control of GSIS.

a Department of Medicine, Stanford University, Stanford, CA 94305, United States

b VA Palo Alto Health Care System, Palo Alto, CA 94304, United States

c Department of Pathology, Stanford University, United States

d Department of Metabolic Disease, University of Tokyo, Tokyo 113, Japan

e Department of Internal Medicine, Jichi Medical School, Tochigi, Japan

Corresponding Author InformationCorresponding author at: Division of Endocrinology S025, Department of Medicine, Stanford University, Stanford, CA 94305-5103, United States. Tel.: +1 650 493 5000x60351; fax: +1 650 849 0215.

PII: S0168-8227(06)00175-6

doi:10.1016/j.diabres.2006.05.001


View previous. 4 of 22 View next.